{"id":27300,"date":"2024-05-02T09:38:09","date_gmt":"2024-05-02T07:38:09","guid":{"rendered":"https:\/\/www.mannheimerswartling.se\/?p=27300"},"modified":"2024-05-02T09:39:12","modified_gmt":"2024-05-02T07:39:12","slug":"lipum-carries-out-a-rights-issue-and-enters-into-a-framework-agreement-regarding-pharmaceutical-manufacturing","status":"publish","type":"post","link":"https:\/\/www.mannheimerswartling.se\/en\/assignment\/lipum-carries-out-a-rights-issue-and-enters-into-a-framework-agreement-regarding-pharmaceutical-manufacturing\/","title":{"rendered":"Lipum carries out a rights issue and enters into a framework agreement regarding pharmaceutical manufacturing"},"content":{"rendered":"<p class=\"preamble\">Lipum has carried out a rights issue of approximately SEK 80 million.<\/p>\n<p>The net proceeds from the rights issue will mainly be used for the completion of the ongoing phase 1 clinical study of the drug lead candidate SOL-116, and for new production of SOL-116 for clinical phase 2 studies in accordance with a framework agreement for e.g. research, development and manufacturing of SOL-116 as an investigational medicinal product that Lipum has entered into with NorthX Biologics AB.<\/p>\n<p>Lipum is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). Lipum\u2019s shares are listed on Nasdaq First North Growth Market (LIPUM).<\/p>\n<p>Lipum was represented by Mannheimer Swartling in connection with the rights issue and the entering into the framework agreement.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lipum has carried out a rights issue of approximately SEK 80 million. The net proceeds from the rights issue will mainly be used for the\u2026<\/p>\n","protected":false},"author":16,"featured_media":27297,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[4313],"tags":[],"class_list":["post-27300","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-assignment","business-group-healthcare-and-life-sciences","business-group-public-ma-and-equity-capital-markets"],"acf":[],"lang":"en","translations":{"en":27300,"sv":27295},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/27300"}],"collection":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/comments?post=27300"}],"version-history":[{"count":1,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/27300\/revisions"}],"predecessor-version":[{"id":27301,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/27300\/revisions\/27301"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media\/27297"}],"wp:attachment":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media?parent=27300"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/categories?post=27300"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/tags?post=27300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}